Chemistry:Gantenerumab
From HandWiki
Short description: Monoclonal antibody protein
_5CSZ.png) | |
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | Beta-amyloid (Aβ40/42) |
| Clinical data | |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6496H10072N1740O2024S42 |
| Molar mass | 146276.71 g·mol−1 |
  (what is this?) (verify) | |
Gantenerumab is a monoclonal antibody for the treatment of Alzheimer's disease being developed by Hoffmann-La Roche pharmaceuticals.[1][2]
Gantenerumab binds to and clears aggregated beta amyloid fibers.[3]
A phase III clinical trial of gantenerumab was stopped early because of a lack of efficacy.[4] Gantenerumab was also evaluated in younger patients at high risk of developing Alzheimer's disease[5] but after five years of treatment, the drug did little to slow cognitive decline in patients.[6]
References
- ↑ "Statement On A Nonproprietary Name Adopted By The Usan Council - Gantenerumab". American Medical Association. http://www.ama-assn.org/ama1/pub/upload/mm/365/gantenerumab.pdf.
- ↑ "International Nonproprietary Names for Pharmaceutical Substances (INN)". World Health Organization. http://whqlibdoc.who.int/druginfo/INN_2008_list59.pdf.
- ↑ "The potential of solanezumab and gantenerumab to prevent Alzheimer's disease in people with inherited mutations that cause its early onset". Expert Opinion on Biological Therapy 18 (1): 25–35. January 2018. doi:10.1080/14712598.2018.1389885. PMID 29037101.
- ↑ "A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease". Alzheimer's Research & Therapy 9 (1): 95. December 2017. doi:10.1186/s13195-017-0318-y. PMID 29221491.
- ↑ Clinical trial number NCT01760005 for "Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. (DIAN-TU)" at ClinicalTrials.gov
- ↑ Kolata, Gina (10 February 2020). "An Alzheimer's Treatment Fails: 'We Don't Have Anything Now'". The New York Times. https://www.nytimes.com/2020/02/10/health/alzheimers-amyloid-drug.html.
 |  |
